Abstract
MisMatch Repair deficiency (dMMR) / Microsatellite instability (MSI) is a crucial biomarker in colorectal cancer (CRC) predictive of response to immunotherapy and Lynch syndrome. Universal screening of newly diagnosed CRC for dMMR/MSI status is now recommended. With the growing numbers of biomarkers screened in clinical practice, dMMR/MSI testing, currently diagnosed by immunohistochemistry (IHC) and/or polymerase chain reaction (PCR), contributes to increasing pathologists workload and delaying therapeutic decisions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
